Related Experiment Videos
In vitro and in vivo suppression of osteoclast function by adenovirus vector-induced csk gene
T Miyazaki1, H Takayanagi, M Isshiki
1Department of Orthopaedic Surgery, Faculty of Medicine, University of Tokyo, Japan.
Abstract:
The proto-oncogene c-src, which encodes a non-receptor-type tyrosine kinase c-Src, has been shown to be essential for osteoclastic bone resorption by the finding that the targeted disruption of the c-src gene induced osteopetrosis in mice. The csk (C-terminal Src family kinase) gene encodes a cytoplasmic protein-tyrosine kinase that specifically phosphorylates the negative regulatory site of c-Src (Tyr-527), thereby inhibiting its kinase activity. To regulate osteoclast function by modulating the kinase activity of c-Src, we constructed an adenovirus vector that carries this gene. The recombinant adenovirus vector carrying csk cDNA induced Csk expression in mouse osteoclast-like cells formed in vitro and clearly reduced c-Src kinase activity in a dose-dependent manner. The expression of Csk caused cytoskeletal disorganization of osteoclast-like cells and strongly suppressed pit-forming activity of the cells in vitro. In addition, the viral vector carrying csk gene dramatically suppressed interleukin-1 alpha-induced bone resorption in vivo. Conversely, kinase-inactive Csk caused an increase in c-Src kinase activity and bone resorbing activity of the cells both in vitro and in vivo, acting as a dominant negative molecule against intrinsic Csk. These findings indicate that the inhibition of c-Src activity by adenovirus vector-mediated csk expression offers an efficient means for inhibiting pathological bone resorption by suppressing osteoclast function.
Insights
Targeting the c-src tyrosine kinase with Csk gene therapy via adenovirus vectors effectively inhibits osteoclast function and pathological bone resorption. This approach offers a novel strategy for treating bone diseases.
Area of Science:
- Molecular Biology
- Cell Biology
- Biochemistry
Background:
- Proto-oncogene c-src encodes tyrosine kinase c-Src, crucial for osteoclastic bone resorption.
- C-terminal Src family kinase (Csk) phosphorylates and inhibits c-Src activity.
- Osteoclast dysfunction contributes to pathological bone resorption.
Purpose of the Study:
- To investigate the potential of adenovirus-mediated Csk gene transfer for regulating osteoclast function.
- To assess the impact of inhibiting c-Src kinase activity on osteoclast-mediated bone resorption in vitro and in vivo.
Main Methods:
- Construction of an adenovirus vector carrying csk cDNA.
- Expression of Csk in mouse osteoclast-like cells and assessment of c-Src kinase activity.
- Evaluation of cytoskeletal organization and pit-forming activity in vitro.
- Assessment of bone resorption in vivo following interleukin-1 alpha stimulation.
Main Results:
- Recombinant adenovirus induced Csk expression, dose-dependently reducing c-Src kinase activity.
- Csk expression led to cytoskeletal disorganization and suppressed osteoclast pit-forming activity.
- Adenovirus-mediated csk delivery significantly inhibited bone resorption in vivo.
Conclusions:
- Adenovirus vector-mediated csk expression effectively inhibits c-Src kinase activity in osteoclasts.
- Suppression of c-Src activity by Csk is a viable strategy for inhibiting pathological bone resorption.
- This gene therapy approach holds promise for treating bone-resorptive diseases.